

Cat. No. MHC-HE456

Description


Source	Recombinant Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGACGVGK peptide.
Accession	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGACGVGK
Molecular Weight	The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Supplied as 0.22 µm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Assay Data**Bis-Tris PAGE**

Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

The purity of Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer is greater than 95% as determined by SEC-HPLC.